Olmesartan medoxomil/Amlodipine/Hydrochlorothiazide Krka 40 mg/10 mg/25 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

olmesartan medoxomil/amlodipine/hydrochlorothiazide krka 40 mg/10 mg/25 mg film-coated tablets

krka, d.d., novo mesto - olmesartan medoxomil; amlodipine; hydrochlorothiazide - film-coated tablet - 40/10/25 milligram(s) - olmesartan medoxomil, amlodipine and hydrochlorothiazide

Olmesartan medoxomil/Amlodipine/Hydrochlorothiazide Krka 40 mg/5 mg/12.5 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

olmesartan medoxomil/amlodipine/hydrochlorothiazide krka 40 mg/5 mg/12.5 mg film-coated tablets

krka, d.d., novo mesto - olmesartan medoxomil; amlodipine; hydrochlorothiazide - film-coated tablet - 40/5/12.5 milligram(s) - olmesartan medoxomil, amlodipine and hydrochlorothiazide

Olmesartan medoxomil/Amlodipine/Hydrochlorothiazide Krka 40 mg/5 mg/25 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

olmesartan medoxomil/amlodipine/hydrochlorothiazide krka 40 mg/5 mg/25 mg film-coated tablets

krka, d.d., novo mesto - olmesartan medoxomil; amlodipine; hydrochlorothiazide - film-coated tablet - 40/5/25 milligram(s) - olmesartan medoxomil, amlodipine and hydrochlorothiazide

Olmesartan medoxomil/Amlodipine/Hydrochlorothiazide Krka 20 mg/5 mg/12.5 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

olmesartan medoxomil/amlodipine/hydrochlorothiazide krka 20 mg/5 mg/12.5 mg film-coated tablets

krka, d.d., novo mesto - olmesartan medoxomil; amlodipine; hydrochlorothiazide - film-coated tablet - 20/5/12.5 milligram(s) - olmesartan medoxomil, amlodipine and hydrochlorothiazide

Olmesartan medoxomil/Amlodipine/Hydrochlorothiazide Krka 40 mg/10 mg/12.5 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

olmesartan medoxomil/amlodipine/hydrochlorothiazide krka 40 mg/10 mg/12.5 mg film-coated tablets

krka, d.d., novo mesto - olmesartan medoxomil; amlodipine; hydrochlorothiazide - film-coated tablet - 40/10/12.5 milligram(s) - olmesartan medoxomil, amlodipine and hydrochlorothiazide

Olmesartan /Amlodipine Mylan 20 mg/ 5 mg film coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

olmesartan /amlodipine mylan 20 mg/ 5 mg film coated tablets

mcdermott laboratories ltd., t/a gerard laboratories - olmesartan medoxomil; amlodpine besilate - film-coated tablet - 20mg/5 milligram(s) - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

Olmesartan /Amlodipine Mylan 40 mg/ 5 mg film coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

olmesartan /amlodipine mylan 40 mg/ 5 mg film coated tablets

mcdermott laboratories ltd., t/a gerard laboratories - olmesartan medoxomil; amlodpine besilate - film-coated tablet - 40mg/5 milligram(s) - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

Olmesartan /Amlodipine Mylan 40 mg/ 10 mg film coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

olmesartan /amlodipine mylan 40 mg/ 10 mg film coated tablets

mcdermott laboratories ltd., t/a gerard laboratories - olmesartan medoxomil; amlodpine besilate - film-coated tablet - 40mg/10 milligram(s) - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE tablet, film coated United States - English - NLM (National Library of Medicine)

olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet, film coated

teva pharmaceuticals usa, inc. - olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10), amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - olmesartan medoxomil 20 mg - olmesartan medoxomil, amlodipine, hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE tablet United States - English - NLM (National Library of Medicine)

olmesartan medoxomil and hydrochlorothiazide tablet

solco healthcare us, llc - olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - olmesartan medoxomil 20 mg - olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see dosage and administration (2)] . lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals